Personalized Antiplatelet Therapy Based on CYP2C19 Genotypes in Chinese ACS Patients Undergoing PCI: A Randomized Controlled Trial.

导出 LinkOut

翻译打印收藏纠错

作者： Xiujin,Shi ^[1] ; Yunnan,Zhang ^[2] ; Yi,Zhang ^[2] ; Ru,Zhang ^[2] ; Baidi,Lin ^[2] ; Jialun,Han ^[2] ; Wenzheng,Li ^[3] ; Zhenwei,Fang ^[1] ; Jialin,Yan ^[2] ; Yifan,Wang ^[2] ; Ze,Zheng ^[3] ; Yuan,Lv ^[3] ; Yang,Lin ^[2]

作者单位： Department of Pharmacy, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. ^[1] Department of Pharmacy, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.;School of Pharmaceutical Sciences, Capital Medical University, Beijing, China. ^[2] Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. ^[3]

关键词 CYP2C19 acute coronary syndrome clopidogrel personalized antiplatelet therapy ticagrelor

DOI 10.3389/fcvm.2021.676954

PMID 34222372

发布时间 2024-08-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in cardiovascular medicine

2021年8卷

676954页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Personalized Antiplatelet Therapy Based on CYP2C19 Genotypes in Chinese ACS Patients Undergoing PCI: A Randomized Controlled Trial.

Frontiers in cardiovascular medicine

相似文献

Frontiers in cardiovascular medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Personalized Antiplatelet Therapy Based on CYP2C19 Genotypes in Chinese ACS Patients Undergoing PCI: A Randomized Controlled Trial.

Frontiers in cardiovascular medicine

相似文献

Frontiers in cardiovascular medicine

相关期刊

检索历史清除